Omeros (NASDAQ:OMER) Lowered to Hold Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Omeros (NASDAQ:OMER) from a Buy to a Hold in a research note issued Sunday.
• Analyst coverage is mixed—two Strong Buy, two Buy, one Hold and one Sell—leading to a MarketBeat consensus of Moderate Buy and an average price target of $40.33, well above the current share price.
• Omeros reported quarterly EPS of $3.14 versus analysts' estimate of -$0.55, and its shares last opened at $13.53 with a market capitalization of about $974 million.

Omeros (NASDAQ:OMER - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Sunday.

A number of other brokerages have also issued reports on OMER. Weiss Ratings reissued a "sell (d-)" rating on shares of Omeros in a research note on Tuesday. D. Boral Capital reiterated a "buy" rating and set a $36.00 price objective on shares of Omeros in a report on Tuesday, April 21st. Zacks Research raised Omeros from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 2nd. Finally, HC Wainwright boosted their target price on Omeros from $20.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $40.33.

Omeros Price Performance

NASDAQ OMER opened at $13.53 on Friday. The firm has a market capitalization of $974.16 million, a price-to-earnings ratio of -27.06 and a beta of 2.53. The company has a 50 day simple moving average of $11.59 and a 200-day simple moving average of $10.72. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $3.14 EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $3.69. On average, analysts predict that Omeros will post -1.54 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC lifted its holdings in Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 1,004 shares during the last quarter. State of Wyoming acquired a new position in Omeros during the fourth quarter valued at approximately $25,000. AQR Capital Management LLC raised its position in shares of Omeros by 7.2% in the fourth quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company's stock valued at $392,000 after purchasing an additional 1,532 shares during the period. ProShare Advisors LLC raised its position in shares of Omeros by 12.1% in the fourth quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company's stock valued at $261,000 after purchasing an additional 1,637 shares during the period. Finally, Cerity Partners LLC lifted its stake in shares of Omeros by 6.1% in the fourth quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company's stock worth $523,000 after buying an additional 1,750 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.